Be in the know about the most anticipated aesthetic procedure.
If you want visible, natural-looking results without the excessive pain and extended recovery time that may be associated with more invasive surgeries or procedures, ellacor may be your answer.
First and only FDA-cleared procedure to non-surgically remove excess skin
of patients showed improvement in moderate to severe wrinkles1
overall patient satisfaction when considering all treatment sides1
Don’t take our word for it. See the results from patients who have experienced the ellacor difference.
3 Months After One ellacor Procedure
Photos courtesy of Henry A. Mentz, MD
6 Months After 2 ellacor Procedures
Photos courtesy of Omar A. Ibrahimi, MD, PhD
ellacor uses hollow needles to remove micro-cores of skin, resulting in an improved appearance of moderate and severe wrinkles in the mid to lower face without evidence of scarring.
ellacor precisely removes cores of skin as it moves across the treatment area.
Specially designed hollow needles penetrate and remove up to 8% of skin without evidence of scarring.
After the skin is removed, the body’s natural healing response quickly closes the cores, resulting in an improved appearance.
ellacor has been recognized in the Innovation Category for Best Nonsurgical Skin-Removal Procedure by NewBeauty.
Technology that is getting noticed
The ellacor® System with Micro-Coring® technology is indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Your medical professional will discuss the following side effects with you prior to treatment. Proper pre- and post-treatment care reduces the risk of these side effects; however, some conditions may or may not resolve over time. Side effects associated with this procedure may include: redness, swelling, bruising, burning, dryness, roughness, tightness/pulling of skin, crusting, pain/discomfort, tenderness, tingling, bleeding, numbness, skin peeling, or circular marks on skin.
Other side effects not commonly observed with this procedure may include: itching, hyper/hypo pigmentation, hematoma, infection, scarring, skin irregularities, skin necrosis, uneven appearance of the treated regions (left and right sides of face), or anesthesia toxicity (anesthesia-related complications may include allergic reaction and possibly death).
The ellacor® procedure should not be used for the treatment of areas of skin with dermatosis (e.g. skin tumors, keloids or in case of predisposition to keloids, solar keratosis, warts, or birthmarks), area within the bony orbital rim; mucous membranes; areas where silicone or synthetic material is implanted.
The ellacor® procedure should not be used on patients that are pregnant or nursing mothers, suffering from open wounds, sores, or irritated skin in the treatment area, have an allergy to stainless steel or allergy to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine. Patients that have a history or presence of any clinically significant bleeding disorder, have dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus should not be treated with the ellacor® procedure. Additionally, patients that have systemic infections or acute local skin infections such as Hepatitis disorders type A, B, C, D, E or F or HIV infection, take a high dose of anti-coagulants or blood-thinning substances (e.g. aspirin, nonsteroidal anti-inflammatory drugs, NSAIDs, warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days), are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area, have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old, have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months, or have scars less than six (6) months old in the treatment area should not be treated with the ellacor® procedure.
Appropriateness for treatment is based on the clinical assessment of the patient by the treating physician. Use caution when treating patients with the following conditions or taking the following medications: